Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Alkermes’ Antipsychotic Combo Faces US FDA Questions On Metabolic Effects, Opioid-Related Safety
Oct 07 2020
•
By
Sue Sutter
ALKS 3831 resulted in less weight gain compared to use of olanzapine alone. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers